Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.PRNewsWire • 07/19/23
Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001PRNewsWire • 06/28/23
Kintara Therapeutics to Participate in the Maxim Group Virtual Healthcare ConferencePRNewsWire • 06/16/23
Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor SocietyPRNewsWire • 05/19/23
Kintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate UpdatePRNewsWire • 05/11/23
Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual MeetingPRNewsWire • 04/14/23
Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual MeetingPRNewsWire • 03/15/23
Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023PRNewsWire • 03/10/23
Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate UpdatePRNewsWire • 02/14/23
Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023PRNewsWire • 01/09/23
Why Kintara Therapeutics Stock Is Seeing Blue Skies Thursday - Kintara Therapeutics (NASDAQ:KTRA)Benzinga • 12/15/22
Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)PRNewsWire • 12/15/22
Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022PRNewsWire • 12/01/22
Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementPRNewsWire • 11/30/22
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast CancerPRNewsWire • 11/28/22
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual MeetingPRNewsWire • 11/18/22
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate UpdatePRNewsWire • 11/09/22
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational StudyPRNewsWire • 10/19/22